Mail

OPNT - Opiant Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

13.50

0.00 (0.00%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	13.50
Open	13.12
Bid	13.11 x 1000
Ask	13.50 x 1100
Day's Range	13.00 - 13.50
52 Week Range	9.98 - 29.55
Volume	11,288
Avg. Volume	20,096

Market Cap	53.937M
Beta (3Y Monthly)	0.36
PE Ratio (TTM)	N/A
EPS (TTM)	-4.08
Earnings Date	Mar 14, 2018 - Mar 19, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	40.00

Trade prices are not sourced from all markets

All

News

Press Releases

Yahoo Finance Video3 months ago
Opiant CEO, creator of Narcan, weighs in on opioid overdose crisis
"This opioid crisis has become a fentanyl crisis," the CEO of Opiant Dr. Roger Crystal told Yahoo Finance's Alexis Christoforous. He then goes on to discuss what else the pharmaceutical company is doing to tackle the epidemic.
Simply Wall St.last month
Can We See Significant Insider Ownership On The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Share Register?
Every investor in Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) should be aware of the most powerful shareholder groups...
Thomson Reuters StreetEvents2 months ago
Edited Transcript of OPNT earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Opiant Pharmaceuticals Inc Earnings Call
Zacks Small Cap Research2 months ago
OPNT: Encouraging Pharmacokinetic Data for OPNT003…
The company recorded a total of $5.4 million in revenue for the three months ending Mar. 31, 2019, which consisted of $3.7 million in royalty revenue from the sale of NARCAN® Nasal Spray, $1.6 million of grant and contract revenue, and $0.08 million from treatment investment revenue. This compares to royalty revenue of $1.6 million for the three months ended Mar. 31, 2018. The increase in royalty revenue is due to the increase in sales of NARCAN® Nasal Spray by Emergent BioSolutions (EBS), which totaled $65.5 million in the first quarter of 2019.
GlobeNewswire2 months ago
Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., May 09, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
GlobeNewswire3 months ago
Opiant Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, May 9
SANTA MONICA, Calif., April 30, 2019 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
Simply Wall St.3 months ago
Announcing: Opiant Pharmaceuticals (NASDAQ:OPNT) Stock Increased An Energizing 249% In The Last Five Years
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) shareholders might be concerned after seeing the share price drop 21% in the last quarter. But that doesn't change the fact that shareholders have received really good returns ov...
Yahoo Finance3 months ago
Pharma CEO: 'This opioid crisis has become a fentanyl crisis'
The opioid crisis has become increasingly worse over the last decade and is estimated to cost the U.S. government nearly $38 billion in lost tax revenue due to employment loss.
GlobeNewswire3 months ago
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic (PK) data for OPNT003, nasal nalmefene containing Intravail® (dodecyl maltoside), were published online in the Journal of Pharmacology and Experimental Therapeutics and presented on Sunday, April 7, 2019, at the American Society for Pharmacology and Experimental Therapeutics 2019 Annual Meeting. The data in this manuscript, titled “Fighting Fire with Fire: Development of Intranasal Nalmefene for Treatment of Synthetic Opioid Overdose,” show that adding the absorption enhancer Intravail® to intranasal nalmefene results in very rapid and robust increases in nalmefene plasma levels with a speed of absorption comparable to intramuscular injection.
GlobeNewswire3 months ago
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic data of OPNT002, nasal naltrexone containing Intravail® (dodecyl maltoside), were published online in The Journal of Clinical Pharmacology.
GlobeNewswire4 months ago
Opiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
SANTA MONICA, Calif., April 01, 2019 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
GlobeNewswire4 months ago
Opiant Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
SANTA MONICA, Calif., March 28, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
Zacks Small Cap Research4 months ago
OPNT: Strong Revenue Growth for NARCAN® Nasal Spray…
On March 21, 2019, Opiant Pharmaceuticals, Inc. (OPNT) announced financial results for the fourth quarter and full year 2018. For the fourth quarter of 2018, Opiant reported total revenue of $4.8 million, with $4.4 million of revenue from the license agreement with Adapt Pharma for the sale of NARCAN® Nasal Spray. For 2018, Opiant had total revenues of $14.0 million, which included $13.3 million of revenue from the sale of NARCAN® Nasal Spray.
GlobeNewswire4 months ago
Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., March 21, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
ACCESSWIRE4 months ago
Opiant Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 21, 2019 / Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 21, 2019 at ...
Benzinga4 months ago
The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 20) AstraZeneca plc (NYSE: AZN ) BioDelivery Sciences ...
GlobeNewswire4 months ago
Opiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21
SANTA MONICA, Calif., March 18, 2019 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
GlobeNewswire5 months ago
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
-Study did not meet primary endpoint- -Company discontinuing development of OPNT001 for treatment of Bulimia Nervosa- -Focus remains on advancing lead product candidate,.
Simply Wall St.5 months ago
Should You Take Comfort From Insider Transactions At Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companies Read More...
ACCESSWIRE5 months ago
LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index
LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...
Zacks Small Cap Research6 months ago
OPNT: Acquires Drinabant for Acute Cannabinoid Overdose…
On December 26, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the acquisition of drinabant, a novel CB-1 receptor antagonist, for the treatment of acute cannabinoid overdose (ACO). Opiant will pay Sanofi an upfront payment of $500,000 and will be responsible for all development and commercialization activities. ACO in adults, which typically occurs from the ingestion of marijuana edibles or the use of synthetic cannabinoids, can result in anxiety, nausea, agitation, and hallucinations.
GlobeNewswire7 months ago
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has entered into an exclusive global licensing agreement with Sanofi (SNY) for the development and commercialization of drinabant for the treatment of acute cannabinoid overdose (ACO). Opiant intends to develop drinabant, a cannabinoid CB-1 receptor antagonist, as an injectable for administration in an emergency department setting.
GlobeNewswire7 months ago
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
SANTA MONICA, Calif., Dec. 24, 2018 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for.
Simply Wall St.8 months ago
Does Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) CEO Salary Reflect Performance?
Roger Crystal has been the CEO of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) since 2009. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...